Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings
详细信息 查看全文
- 作者：Rodrigo Barbosa de Aguiara ; b ; Carolina Bellini Pariseb ; Carolina Rosal Teixeira Souzaa ; Camila Braggionb ; Wagner Quintilioc ; Ana Maria Moroc ; Fabio Luiz Navarro Marquesd ; Carlos Alberto Buchpigueld ; Roger Chammasa ; rchammas@usp.br" class="auth_mail" title="E-mail the corresponding author ; Jane Zveiter de Moraesb ; janezvmo@gmail.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：FGF2 ; Melanoma ; Monoclonal antibody ; Angiogenesis ; Metastasis
- 刊名：Cancer Letters
- 出版年：2016
- 出版时间：28 February 2016
- 年：2016
- 卷：371
- 期：2
- 页码：151-160
- 全文大小：2882 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
The anti-FGF2 monoclonal antibody (mAb) 3F12E7 is able to neutralize its target.
- class="label">•
Anti-FGF2 mAb achieves B16-F10 tumors and impairs its outgrowth.
- class="label">•
Anti-FGF2 mAb treatment decreased vascular density in B16-F10 metastases.
- class="label">•
Anti-FGF2 mAb treatment impairs melanoma metastasis in adjuvant settings.